Calistoga Initiates Phase I Hematologic Cancer Trial
July 11, 2008
Calistoga Pharmaceuticals has initiated a Phase I clinical trial of its lead compound, CAL-101, a small molecule phosphoinositide-3 kinase delta inhibitor, in patients with hematologic cancer.
This open label trial will explore the safety and clinical activity of CAL-101 in patients with chronic lymphocytic leukemia, selected B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
Albert Yu, vice president of clinical affairs and chief medical officer of Calistoga, said: “We at Calistoga are very pleased to be entering our first oncology trial. PI3K delta is a novel target in cancer, and we look forward to evaluating CAL-101 as a potential treatment to improve outcomes in patients with certain types of leukemias and lymphomas.”